당뇨병 치료용 임상 영양 시장, 시장 기회, 성장 촉진요인, 산업 동향 분석 및 예측(2024-2032년)

Clinical nutrition for diabetes care market size is set to record a 4.8% CAGR during 2024-2032 driven by the global rise in diabetes prevalence and the growing acknowledgment of the pivotal role of diets in managing the condition. As per WHO, around 422 million people have diabetes globally. Clinical nutrition products designed specifically for diabetes care, such as low glycemic index foods, fiber-rich supplements, and nutrient-enriched meal replacements, help manage blood glucose levels and improve overall health.

Advancements in product formulations and the creation of tailored nutritional plans, aligned with individual metabolic profiles and health conditions, are amplifying the efficacy of dietary interventions in diabetes management. As a result, healthcare professionals and dietitians are increasingly integrating these specialized nutrition products into holistic diabetes care plans, driving up market demand.

The overall industry is classified into product, disease type, consumer, dosage form, distribution channel, and region.

Based on product, the clinical nutrition for diabetes care market size from the parenteral nutrition segment is expected to generate notable revenue by 2032. This is due to its ability to provide crucial nutritional support for patients unable to meet dietary needs through oral means. Parenteral nutrition offers a meticulous approach to nutrient administration, including solutions for glucose management, especially beneficial for individuals grappling with severe diabetes or gastrointestinal challenges.

With respect to dosage form, the clinical nutrition for diabetes care market from the liquid segment is projected to observe a robust CAGR during 2024 - 2032. This growth is attributed to the convenience and digestibility of liquid nutritional solutions, which are specifically tailored for diabetic patients. Products like meal replacements and therapeutic beverages are crafted to deliver balanced nutrition with regulated carbohydrate content, aiding in effective blood glucose management.

Asia Pacific the clinical nutrition for diabetes care industry size will grow substantially between 2024 and 2032. This surge is linked to the region's rising diabetes prevalence, heightened healthcare awareness, and better access to specialized nutrition products. With countries like China, India, and Japan witnessing escalating diabetes rates, there is an amplified demand for effective clinical nutrition solutions.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of diabetes
    • 3.2.1.2 Advancements in clinical nutrition
    • 3.2.1.3 Growing geriatric population
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Limited awareness in developing economies
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Porter's analysis
• 3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Oral nutrition
  • 5.2.1 Not ready-to-use
  • 5.2.2 Ready-to-use
    • 5.2.2.1 Liquids
    • 5.2.2.2 Solids
• 5.3 Parenteral nutrition
  • 5.3.1 Macronutrients
    • 5.3.1.1 Carbohydrates
    • 5.3.1.2 Amino acids
    • 5.3.1.3 Lipids
  • 5.3.2 Micronutrients
    • 5.3.2.1 Vitamins
    • 5.3.2.2 Minerals
• 5.4 Enteral feeding formulas
  • 5.4.1 Standard composition
  • 5.4.2 Disease specific composition

Chapter 6 Market Estimates and Forecast, By Disease Type, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Type 2 diabetes
• 6.3 Type 1 diabetes

Chapter 7 Market Estimates and Forecast, By Consumer, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Adult
• 7.3 Pediatric

Chapter 8 Market Estimates and Forecast, By Dosage Form, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Powder
• 8.3 Liquid
• 8.4 Solid

Chapter 9 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 Retail pharmacies
• 9.3 Hospital pharmacies
• 9.4 Online pharmacies
• 9.5 Other distribution channels

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 10.1 Key trends
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 France
  • 10.3.4 Spain
  • 10.3.5 Italy
  • 10.3.6 Netherlands
  • 10.3.7 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 China
  • 10.4.2 Japan
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 South Korea
  • 10.4.6 Rest of Asia Pacific
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
  • 10.5.3 Rest of Latin America
• 10.6 Middle East and Africa
  • 10.6.1 South Africa
  • 10.6.2 Saudi Arabia
  • 10.6.3 UAE
  • 10.6.4 Rest of Middle East and Africa

Chapter 11 Company Profiles

• 11.1 Abbott Laboratories
• 11.2 Baxter International Inc.
• 11.3 B Braun Melsungen AG
• 11.4 Danone Nutricia
• 11.5 Dr Reddy's Laboratories Ltd.
• 11.6 Mead Johnson and Company, LLC
• 11.7 Nestle Health Science S.A.
• 11.8 Nutrego
• 11.9 Otsuka Holdings Co., Ltd.
• 11.10 Pfizer Inc.
• 11.11 Prohance
• 11.12 Victus, Inc.